ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1271

Post-Traumatic Stress Disorder (PTSD) and Risk of Systemic Lupus Erythematosus (SLE) Among Medicaid Recipients

Siobhan Case1, Candace Feldman1, Hongshu Guan1, Laura Kubzansky2, Karestan Koenan2 and Karen Costenbader3, 1Brigham and Women's Hospital, Boston, MA, 2Harvard T.H. Chan School of Public Health, Boston, MA, 3Brigham and Women's Hospital and Harvard Medical School, Boston, MA

Meeting: ACR Convergence 2020

Keywords: mental health, psychosocial factors, risk factors, Systemic lupus erythematosus (SLE)

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Sunday, November 8, 2020

Title: SLE – Diagnosis, Manifestations, & Outcomes Poster II: Comorbidities

Session Type: Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: Post-traumatic stress disorder (PTSD), the sentinel stress-related mental disorder, may be associated with increased risk of developing autoimmune disease, including systemic lupus erythematosus (SLE). This study aimed to study the relationship between PTSD and risk of SLE in a large, diverse population of Medicaid enrollees. We hypothesized patients with incident SLE would be more likely to have a prior diagnosis of PTSD than those without SLE.

Methods: We performed a case-control study using patients ages 18 to 65 years old in the Medicaid Analytic eXtract (MAX) database between January 1, 2007 and December 31, 2010. Cases of SLE were defined as having >3 ICD-9 codes for SLE from hospital discharge diagnoses or physician visit claims, occurring at least 30 days apart. Index date was defined as the date of the first code for SLE. Controls were matched to SLE cases for age, sex and race using a 1:10 ratio. Controls were patients without any claims for SLE, but who had another inpatient or outpatient claim in Medicaid on the SLE index date of the matched case. Exclusion criteria included having less than 12 months of continuous Medicaid enrollment prior to the index or matched control date. The exposure was PTSD, defined as having >2 ICD-9 codes for PTSD on different dates within 4 months of each other, occurring prior to the index date for SLE (Gravely, 2011; PPV 82%). We used conditional logistic regression to calculate the odds ratio (OR) and 95% confidence interval (CI) for history of PTSD prior to index date in cases vs. controls. Finally, we used multivariable analysis to adjust for variables collected prior to the index date, including area-level socioeconomic status (SES), smoking, obesity, oral contraception use, and time enrolled in Medicaid.

Results: We identified 10,942 cases of incident SLE, who were matched to 109,420 controls. There were significant differences at the index date in several characteristics, including zip code level income as a measure of socioeconomic status (SES), US region of residence, smoking, obesity, and oral contraceptive use (Table 1). 1.46% of Medicaid enrollees with SLE met the definition of PTSD prior to the index date, compared to 0.75% of controls (p< 0.001). The OR for PTSD and risk of incident SLE was 1.96 (95% CI 1.66-2.33, p< 0.001) in conditional logistic regression, and 2.02 (95% CI 1.65-2.48, p< 0.001) after multivariable adjustment (Table 2). Further adjustment for the matching factors did not alter risk estimates.

Conclusion: In this large, racially and sociodemographic diverse US patient population, we found a near doubling of odds of SLE associated with prior PTSD diagnosis. Chronic stress leading to hypothalamic-pituitary axis dysregulation and inflammatory cytokine upregulation are postulated mechanisms. Future studies are needed with longer follow-up time to clarify the underlying pathophysiology and characterize modifying influences in the relationship between PTSD and SLE.


Disclosure: S. Case, None; C. Feldman, Biogen, 8, Voyager Therapeutics, 5, Merck, 5; H. Guan, None; L. Kubzansky, None; K. Koenan, None; K. Costenbader, Glaxo Smith Kline, 5, UpToDate, 7, Lupus Foundation of America, 6, Neutrolis Inc, 5.

To cite this abstract in AMA style:

Case S, Feldman C, Guan H, Kubzansky L, Koenan K, Costenbader K. Post-Traumatic Stress Disorder (PTSD) and Risk of Systemic Lupus Erythematosus (SLE) Among Medicaid Recipients [abstract]. Arthritis Rheumatol. 2020; 72 (suppl 10). https://acrabstracts.org/abstract/post-traumatic-stress-disorder-ptsd-and-risk-of-systemic-lupus-erythematosus-sle-among-medicaid-recipients/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to ACR Convergence 2020

ACR Meeting Abstracts - https://acrabstracts.org/abstract/post-traumatic-stress-disorder-ptsd-and-risk-of-systemic-lupus-erythematosus-sle-among-medicaid-recipients/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology